Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients by Figenschau, Stine Linn et al.
Figenschau et al. BMC Cancer  (2015) 15:101 
DOI 10.1186/s12885-015-1116-1RESEARCH ARTICLE Open AccessTertiary lymphoid structures are associated with
higher tumor grade in primary operable breast
cancer patients
Stine L Figenschau1, Silje Fismen2, Kristin A Fenton1, Christopher Fenton3 and Elin S Mortensen1,2*Abstract
Background: Tertiary lymphoid structures (TLS) are highly organized immune cell aggregates that develop at sites of
inflammation or infection in non-lymphoid organs. Despite the described role of inflammation in tumor progression,
it is still unclear whether the process of lymphoid neogenesis and biological function of ectopic lymphoid tissue in
tumors are beneficial or detrimental to tumor growth. In this study we analysed if TLS are found in human breast
carcinomas and its association with clinicopathological parameters.
Methods: In a patient group (n = 290) who underwent primary surgery between 2011 and 2012 we assessed the
interrelationship between the presence of TLS in breast tumors and clinicopathological factors. Prognostic factors
were entered into a binary logistic regression model for identifying independent predictors for intratumoral TLS
formation.
Results: There was a positive association between the grade of immune cell infiltration within the tumor and
important prognostic parameters such as hormone receptor status, tumor grade and lymph node involvement. The
majority of patients with high grade infiltration of immune cells had TLS positive tumors. In addition to the degree of
immune cell infiltration, the presence of TLS was associated with organized immune cell aggregates, hormone
receptor status and tumor grade. Tumors with histological grade 3 were the strongest predictor for the presence of
TLS in a multivariate regression model. The model also predicted that the odds for having intratumoral TLS formation
were ten times higher for patients with high grade of inflammation than low grade.
Conclusions: Human breast carcinomas frequently contain TLS and the presence of these structures is associated
with aggressive forms of tumors. Locally generated immune response with potentially antitumor immunity may
control tumorigenesis and metastasis. Thus, defining the role of TLS formation in breast carcinomas may lead to
alternative therapeutic approaches targeting the immune system.
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A growing number of publications has described the
complex architecture of immune cell infiltration in hu-
man solid tumors [1]. Immune responses may develop
ectopically at sites of inflammation or infection inde-
pendently of secondary lymphoid organs [2-4]. The cellular* Correspondence: elin.s.mortensen@uit.no
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unless otherwise stated.composition of immune cell infiltrates in the tumor
microenvironment varies and is heterogeneous, con-
taining innate immune cells such as macrophages,
dendritic cells, natural killer cells, granulocytes and
mast cells [1]. In addition cells of the adaptive linages,
B and T lymphocytes have been observed. Premalig-
nant and in situ lesions, as well as invasive carcinomas
of the breast, contain immune cell infiltrates in the
neoplastic stroma, indicating that the tumor progres-
sion is linked to abundant infiltration of immune cells
[5]. Several studies support the notion that spontan-
eous adaptive responses can be elicited by the hosttral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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anti-tumor response rather than randomly recruited
lymphocytes from the circulation [6-9]. The notable
presence of these immune cells, especially the lympho-
cytes and antigen presenting dendritic cells, has pro-
vided evidence that certain tumors can elicit such an
immune response. The development of ectopic lymph-
oid tissue, or tertiary lymphoid structures (TLS), in
tumors has been described in several other neoplastic
diseases such as lung cancer [10,11], colorectal cancer
[12,13], malignant melanoma [14,15], as well as being
a key feature of chronic inflammatory autoimmune
and infectious diseases, including rheumatoid arthritis
[16,17], Sjögren’s syndrome [18,19], and Helicobacter
pylori-induced gastritis [20,21].
TLS that develop within the tumor resemble the
organization of immune cells in secondary lymphoid
organs, in that they contain follicles comprising B lym-
phocytes and follicular dendritic cells (FDC), with sur-
rounding areas of T lymphocytes and subpopulations
of dendritic cells (DC). Following antigen stimulation,
B lymphocytes and follicular helper T (Tfh) cells in
the B cell zone of these follicles express Bcl6 which is
unique for germinal centers (GC) [22]. High endothe-
lial venules (HEV), blood vessels specialized for regula-
tion of lymphocyte trafficking from lymphatic organs
into peripheral tissues, are also described in breast
tumors [23]. HEV are participating in the development
and maintenance of chronic inflammation as they are
essential for regulating the extravasation of lympho-
cytes into the inflamed areas and tumor tissue. HEV
are normally not found in non-neoplastic tissue. They
are generally restricted to lymphoid tissues and organs,
indicating the importance of specialized vascular sys-
tems in the development of TLS [23].
The patient’s prognosis and the clinical outcome of
breast cancer are influenced by tumor related factors,
including histological tumor grade, tumor size, lymph
node involvement and hormone receptor status [24].
Several studies describe the relationship between im-
mune contexture in tumors and the impact on patients’
clinical outcome. Tumors with higher numbers of im-
mune cell infiltrates, especially lymphocytes, are in gen-
eral associated with improved survival [25,26]. Patients
with tumor infiltrating T lymphocyte populations are
shown to have favourable clinical outcome, especially
tumors with higher levels of CD8+ T lymphocytes are
associated with better patient survival rates [27-29]. Even
though tumor infiltrating CD20+ B lymphocytes play a
role in anticancer immune responses and are a common
occurrence in breast tumors [9,30], the role in patients’
clinical outcome is still unclear. It is postulated that B
lymphocytes are an independent predictor associated
with patients’ outcome and associated with higher tumorgrade [31,32]. However, the current opinion is based on
conflicting results, suggesting that further studies have
to determine whether B lymphocytes play a role in
tumor progression and in prediction of cancer specific
survival [33].
Consistent with previous findings, tumors behave as
triggers for inflammation and the complex interaction
between tumor cells and the host inflammatory response
is a key feature of carcinogenesis [5,34]. Several studies
have shown an important relationship between tumor
infiltrating immune cells and the clinical outcome for
breast cancer patients. However, it is still unclear if a
locally produced immune response, with the formation
of TLS within the tumor will have an influence on the
development of cancer and patients survival. Although
the presence of organized immune cell aggregates in pri-
mary operable breast cancers has been shown previously
[6,8,22,23,35-37], this is, to our knowledge, the first time
the characterization of TLS has been described in a
larger patient group of breast carcinomas with its associ-
ation to clinicopathological features. Taken together, our
main results showed more organized immune cell aggre-
gates in tumors with higher grade of immune cell
infiltration compared with less inflamed tumors. The
presence of intratumoral TLS was associated with higher
degree of immune cell infiltration and higher histological
tumor grade.
Methods
This study was approved by the Regional Committees
for Medical and Health Research Ethics (REC; Norway,
2010/1523). All analyses were performed on tissue speci-
men previously collected for diagnostic purposes. The
study was considered of significant interest for society,
the participant’s welfare and integrity was safeguarded
and the material was anonymized. Since all these criteria
were fulfilled the Regional Ethics committee agreed to
use the material for study purposes.
Clinical samples
This study was conducted on patients who underwent
primary surgery between 2011 and 2012 at the Univer-
sity hospital of North Norway (UNN), Tromsø. We
used archived formalin-fixed paraffin-embedded (FFPE)
specimens obtained from the Department of Pathology
(UNN) with the corresponding hematoxylin and eosin
(HE) slides from all patients. A total of 290 patients
with invasive carcinoma of no special type (NST),
formerly known as invasive ductal carcinoma (IDC)
[38], invasive lobular carcinoma (ILC), ductal carcin-
oma in situ (DCIS) and other types of invasive breast
carcinomas were included in the study. None of the
patients included in this study received adjuvant ther-
apy before surgery, nor did they have any other known
Table 1 Patients’ demographics and clinicopathological
characteristics (n = 290)











Invasive carcinomas without DCIS 93 (36.3)
Invasive carcinomas with DCIS 163 (63.7)
DCIS grade
DCIS grade 1-2 77 (39.3)
DCIS grade 3 119 (60.7)
Hormone receptor status
ER neg / pos / na 44 (15.2) / 210 (72.4) / 36 (12.4)
PR neg / pos / na 59 (20.3) / 122 (42.1) / 109 (37.6)
HER2 neg / pos / na 215 (74.1) / 40 (13.8) / 35 (12.1)
Tumor size
≤20 mm 159 (62.1)
21- 50 mm 87 (34.0)












No infiltration 39 (13.5)
Mild infiltration 144 (49.8)
Moderate infiltration 90 (31.1)




Table 1 Patients’ demographics and clinicopathological




Abbreviations: NST invasive carcinoma of no special type, ILC invasive lobular
carcinoma, DCIS ductal carcinoma in situ, other invasive carcinomas include:
tubular carcinoma, cribriform carcinoma, mucinous carcinoma, medullary
carcinoma, apocrine carcinoma, metaplastic carcinoma, papillary carcinoma,
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal
growth factor receptor 2, TLS tertiary lymphoid structures, na not analysed.
*Patient(s) data missing.
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clinicopathological characteristics are shown in Table 1.
DCIS grade was evaluated according to the Van Nuys
classification [39]. Histological tumor grade was assessed
by the Nottingham Grading System [40]. The cut off
values for Estrogen (ER) and progesterone (PR) were 10%.
Tumors demonstrating HER2 protein overexpression or
amplified HER2 gene (IHC 3+ or FISH HER2 gene ratio
≥2) were considered to be positive.
Assessment of tumor immune cell infiltrate
Histopathological analysis of full-faced HE stained tissue
sections were used to assess the overall level of immune
cell infiltration in the breast tumors. Using routine hist-
ology, the patient samples were evaluated based on the
total amount of immune cell infiltrate, both in the cen-
tral areas of the tumor and at the invasive margin, then
categorized into the following groups: no immune cell
infiltrate, mild infiltrate, moderate infiltrate and exten-
sive immune cell infiltrate. By applying this definition,
we further divided the categories into two groups: low
grade and high grade infiltration of immune cells. The
two pathologists (ESM and SF) independently performed
the categorizing and had no knowledge of the patients’
background history.
Immunohistochemistry
Tumor samples that contained organized aggregates of
immune cells, judged by HE staining, were further
assessed by immunohistochemical analyses. FFPE serial
sections (4 μm) were deparaffinized and dehydrated in
xylene and graded alcohols. Antigen retrieval was per-
formed by microwave treatment in 10 mM sodium
citrate buffer (pH 6.0) for 20 min. Endogenous peroxid-
ase activity was blocked with 3% H2O2 for 10 min and
non-specific binding was blocked with 10% goat serum
(Invitrogen™, Life Technologies) for 30 min. Sections
were incubated with unlabelled primary antibody for
30 min and Polink-2 HRP Plus DAB kit (Golden Bridge
International, Inc., USA) was used as detection system
according to the manufacturers’ protocol. For the detec-
tion of PNAd +HEV, sections were incubated with purified
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antibody (1:500, AP202P; Millipore) for 30 min prior to
reaction with DAB substrate-chromogen (Golden Bridge
International, Inc., USA). Finally, sections were counter-
stained with hematoxylin and rehydrated in graded alco-
hols and xylene. All reactions were performed at room
temperature, if not stated otherwise. Human lymph node,
tonsil and breast tumor were used as positive controls.
Negative controls were performed by omitting the primary
antibody. Immunohistochemical analyses using the plat-
form specific assays on BenchMark XT (Ventana Medical
systems Inc., USA) were performed according to the
manufacturers’ instructions. Antibodies used for immuno-
histochemical analyses are summarized in Table 2.Statistical analyses
Determination of interobserver agreement was assessed
by the Cohen’s kappa statistics (κ). Values of κ from 0.60
to 0.79 are considered good, and above 0.80 excellent.
Baseline descriptive statistics are reported as frequencies
and percentages. Interrelationship between variables was
assessed using contingency tables; Phi analyses for
dichotomous variables and Spearman rank order correl-
ation for ranked data. The variables with the highest
level of significance and important prognostic factors
were entered into a regression model. Binary logistic
regression analysis with the fixed entry method was per-
formed in order to identify significant predictors for the
presence of TLS in patient tumors. The following diag-
nostic predictors were included in the regression analysis
together with the lymphocytic parameters: tumor size,
histology grade and clinical nodal status. For all statis-
tical analyses, if not stated otherwise, p values < 0.05
(two-tailed) were considered statistically significant. Stat-
istical analyses were performed using SPSS software
version 22 (SPSS Inc., Chicago, IL, USA).Table 2 Primary antibodies used for immunohistochemical an
Antigen Manufacturer Cat. no Clone
Bcl6 Ventana 760-4241 GI191E/A8
CD3 Ventana 790-4341 2GV6
CD4 Ventana 790-4423 SP35
CD8 Ventana 790-4460 SP57
CD20 Ventana 760-2531 L26
CD21 Ventana 760-4245 2G9
CD21 Ventana 760-4438 EP3093
CD21 Abcam ab75985 EP3093
ER Ventana 790-4325 SP1
PR Ventana 790-4296 1E2
HER2/neu Ventana 790-2991 4B5
PNAd Biolegend 120801 MECA-79Results
The demographics and baseline clinicopathological cha-
racteristics of patients with primary operable breast
carcinomas included are shown in Table 1.Characterization of tertiary lymphoid structures in breast
carcinomas
Tumors from all patients who underwent primary sur-
gery in the period 2011 to 2012 were categorized into
four groups based on the degree of immune cell infil-
tration as shown in Figure 1A-D. The distribution of
patient samples showed that 13.5% had no immune
cell infiltration (Figure 1A), 49.8% had mild infiltration
(Figure 1B), 31.1% had moderate infiltration (Figure 1C),
and 5.6% were categorized as tumors with extensive infil-
tration of immune cells (Figure 1D and Table 1). The
interobserver κ value for the categorical parameter (no
infiltrate, mild infiltrate, moderate infiltrate, extensive
infiltrate) was 0.78 (p <0.001).
The organization of tumor infiltrating immune cells
was characterized by immunohistochemical detection
(Figures 2 and 3). The immune cell aggregates which
were TLS positive showed the presence of CD20+ B lym-
phocytes within the follicles, with areas of CD3+ T lym-
phocytes resembling the highly organized structures of
secondary lymphoid organs (Figure 2B and C). CD21+
FDC formed a tight network in the B cell zone within the
follicle as shown in Figure 3A and B. Consistent with pre-
vious findings [9], the majority of CD3+ T lymphocytes
in the T cell zone were of the CD4+ T cell subset
(Figure 3C). CD8+ T lymphocytes were moderately
dispersed within the T cell zone (Figure 3D). More-
over, Figure 3E shows Bcl6+ GC B lymphocytes and
Tfh cells which were detected in most of the orga-
nized lymphoid aggregates. HEV, although restricted
to lymphoid tissue, were also found in the tumoralyses
Species Control Dilution
Mouse IgG1 Lymph node Pre-diluted
Rabbit IgG Lymph node Pre-diluted
Rabbit Lymph node Pre-diluted
Rabbit Lymph node Pre-diluted
Mouse IgG2a/κ Lymph node Pre-diluted
Mouse IgG2a Lymph node Pre-diluted
Rabbit IgG1 Lymph node Pre-diluted
Rabbit IgG Tonsil 1:100
Rabbit IgG Breast carcinoma Pre-diluted
Rabbit IgG Breast carcinoma Pre-diluted
Rabbit Breast carcinoma Pre-diluted
IgM,κ Lymph node 1:50
Figure 1 Characterization of immune cell infiltrate in breast carcinomas. Invasive human breast carcinomas with A) no immune cell
infiltrate B) mild infiltrate C) moderate infiltrate and D) extensive infiltrate. All slides are HE stained and at the same magnification (100X).
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found in the T cell area of the lymphoid aggregates as
shown in Figure 3F. These vessels were not found at
other sites than within the TLS, nor in non-cancerous
areas of the breast (results not shown). Histopatho-
logical analyses revealed immune cell infiltrates with
aggregate formation in 50.5% of the patient samples
of which 38.6% were TLS positive (Table 1). Intratu-
moral TLS formation was found both in the periphery
of the tumor, the centre of the tumor as well as close
to adjacent tumor nests. The extent and size of theseFigure 2 Representative overview of lymphocytic infiltrate in breast t
breast tumor biopsies show the localization and distribution of lymphocyte
TLS with GC, B) CD20+ B lymphocytes forming follicles with surrounding a
of secondary lymphoid tissue. Magnification 20X. Higher magnification of bstructures within the tumor varied in the patient
samples.
Association between immune cell infiltration and
clinicopathological parameters
The relationship between the degree of immune cell
infiltration in tumors and patients’ clinicopathological
characteristics are shown in Table 3. The majority of the
patients who had tumor with high grade immune cell
infiltration (n = 106) were over 50 years, had invasive
carcinoma (NST) and accompanying DCIS componentumor. Histology and immunohistochemical analyses performed on
s in primary tumor of the breast. A) HE staining shows intratumoral
rea of C) CD3+ T lymphocytes, resembling highly organized structures
oxed area is shown in Figure 3.
Figure 3 Characterization of tertiary lymphoid structures in breast carcinoma. Immunohistochemical detection of the indicated antigens in
serial sections of breast carcinoma with extensive immune cell infiltration. Tertiary lymphoid structures with germinal center formation were
detected by A) CD20+ B lymphocyte follicle comprising a network of B) CD21+ FDC, with C) CD4+ and D) CD8+ T lymphocytes in the T cell
zone. E) Bcl6+ germinal center B lymphocytes and Tfh cells were also observed within the B cell follicle with surrounding F) PNAd + HEV like
vessels. Positively stained antigens are shown by brown DAB staining. Magnification 100X.
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cantly associated with higher grade of immune cell
infiltration. ER and PR hormone receptor status were
negatively associated (rϕ = −0.394 and −0.342, respect-
ively, p < 0.01) with the grade of immune cell infiltra-
tion compared with HER2 status which was positively
associated (rϕ = 0.294, p < 0.01). There was a positive
association between the total level of immune cell
infiltration in tumors and tumor grade (rs = 0.384, p <
0.01). Patients who had higher grade of immune cell
infiltration also had higher tumor grades, where 47.2%
of the patients had tumor grade 2 and close to 40%
had tumor grade 3. There was a weak positive associ-
ation between the level of immune cell infiltrate and
lymph node invasion (rϕ = 0.180, p < 0.01).Association between TLS formation and
clinicopathological parameters
The association between the presence of TLS in tumors
and patients’ clinicopathological characteristics are shown
in Table 4. There was a strong positive association (rϕ =
0.796, p < 0.01) between detection of TLS and immune
cell aggregates formed in tumors. Tumor grade and the
level of immune cell infiltration were weakly associated
with TLS formation (rϕ = 0.294 and 0.567, respectively,
p < 0.01). We observed a negative association between
TLS formation and ER and PR positive tumors as
more TLS negative tumors were ER and PR positive
(rϕ = −0.342 and −0.308, respectively, p < 0.01). A weak
association between TLS positive tumors and the pres-
ence of HER2 receptor was observed within the tumors
Table 3 Association between immune cell infiltration grade in tumors and clinicopathological parameters
Low grade immune
cell infiltrate (n = 183)
High grade immune
cell infiltrate (n = 106)
r value p value
Age (≤50 / >50 years) 36 (19.7) / 147 (80.3) 24 (22.6) / 82 (77.4) rφ = −0.035 0.549
Invasive carcinoma (NST) / ILC / DCIS /
Other invasive carcinomas
130 (71.0) / 22 (12.0) / 16 (8.7) / 15 (8.2) 77 (72.6) / 9 (8.5) / 17 (16.0) / 3 (2.8) rs = −0.019 0.743
DCIS status (Invasive DCIS − / Invasive DCIS +) 61 (36.7) / 105 (63.3) 31 (34.8) / 58 (65.2) rφ = 0.019 0.761
DCIS grade (1–2 / 3) 62 (51.2) / 59 (48.8) 15 (20.0) / 60 (80.0) rφ = 0.311 <0.01
Estrogen receptor status (ER − / ER +) 10 (6.1) / 154 (93.9) 33 (37.1) / 56 (62.9) rφ = −0.394 <0.01
Progesterone receptor status (PR − / PR +) 20 (18.9) / 86 (81.1) 38 (51.4) / 36 (48.6) rφ = −0.342 <0.01
HER2 status (HER2 − / HER2 +) 152 (92.1) / 13 (7.9) 62 (69.7) / 27 (30.3) rφ = 0.294 <0.01
Tumor size (≤20 / 21–50 / >50 mm) 111 (66.9) / 47 (28.3) / 8 (4.8) 47 (52.8) / 40 (44.9) / 2 (2.2) rs = 0.122 0.052
Tumor grade (I / II / III) 72 (43.6) / 78 (47.3) / 15 (9.1) 13 (14.6) / 42 (47.2) / 34 (38.2) rs = 0.384 <0.01
Lymph node (− / +) 140 (76.5) / 43 (23.5) 63 (59.4) / 43 (40.6) rφ = 0.180 <0.01
Involved lymph node (0 / 1–3 / >3) 140 (76.5) / 33 (18.0) / 10 (5.5) 63 (59.4) / 29 (27.4) / 14 (13.2) rs = 0.187 <0.01
Abbreviations: NST invasive carcinoma of no special type, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, ER estrogen receptor, PR progesterone
receptor, HER2 human epidermal growth factor receptor 2, rs spearman rank order correlation, rφ phi coefficient. A small number of patients did not have
complete data. Data presented as n (%).
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negative (rϕ = 0.243, p < 0.01).
In order to identify significant predictors for intra-
tumoral TLS formation a regression analysis was con-
ducted using a fixed entry model. The variables of
interest that were entered into the binary logistic re-
gression model are shown in Table 5. Histological
tumor grade 2 and 3 were associated with TLS forma-
tion in univariate analysis. Accordingly, multivariate
regression analysis identified tumor grade 3 as inde-
pendent predictor for TLS formation. As shown inTable 4 Association between presence of tertiary lymphoid st
TLS negative tumors (n = 1
Age (≤50 / >50 years) 38 (21.7) / 137 (78.3)
Invasive carcinoma (NST) / ILC / DCIS /
Other invasive carcinomas
122 (69.7) / 22 (12.6) / 18 (10
DCIS status (Invasive DCIS − / Invasive DCIS +) 59 (37.8) / 97 (62.2)
DCIS grade (1–2 / 3) 52 (45.2) / 63 (54.8)
Estrogen receptor status (ER − / ER +) 10 (6.5) / 144 (93.5)
Progesterone receptor status (PR − / PR +) 20 (19.6) / 82 (80.4)
HER2 status (HER2 − / HER2 +) 141 (91.0) / 14 (9.0)
Tumor size (≤20 / 21–50 / >50 mm) 99 (63.5) / 48 (30.8) / 9 (5.8)
Tumor grade (I / II / III) 64 (41.3) / 75 (48.4) / 16 (10.
Lymph node (− / +) 130 (74.3) / 45 (25.7)
Involved lymph node (0 / 1–3 / >3) 130 (74.3) / 34 (19.4) / 11 (6.
Immune cell infiltration (low / high) 149 (85.1) / 26 (14.9)
Aggregate formation (− / +) 143 (81.7) / 32 (18.3)
Abbreviations: TLS tertiary lymphoid structures, NST invasive carcinoma of no specia
estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor
number of patients did not have complete data. Data presented as n (%).Table 5, the odds ratio of 2.78 [CI, 1.06-7.27] indi-
cates that the odds for having TLS positive tumors
were almost three times more likely for grade 3 tu-
mors than for patients with grade 1 tumors. Another
significant independent parameter was the degree of
immune cell infiltration. The model predicts that the
odds of having TLS formation in tumors were more
than 10 times higher for patients with higher grade of
inflammation than lower graded infiltrated tumors.
Hence, patients with high grade inflammation are two
times more likely to have TLS formation than not.ructures in tumors and clinicopathological parameters
75) TLS positive tumors (n = 110) r value p value
21 (19.1) / 89 (80.9) rφ = 0.032 0.595
.3) / 13 (7.4) 81 (73.6) / 9 (8.2) / 15 (13.6) / 5 (4.5) rs = −0.038 0.518
30 (31.6) / 65 (68.4) rφ = 0.063 0.316
24 (30.0) / 56 (70.0) rφ = 0.153 <0.05
31 (32.6) / 64 (67.4) rφ = −0.342 <0.01
36 (48.6) / 38 (51.4) rφ = −0.308 <0.01
69 (72.6) / 26 (27.4) rφ = 0.243 <0.01
56 (58.9) / 38 (40.0) / 1 (1.1) rs = 0.025 0.694
3) 19 (20.0) / 45 (47.4) / 31 (32.6) rs = 0.294 <0.01
70 (63.6) / 40 (36.4) rφ = 0.113 0.056
3) 70 (63.6) / 27 (24.5) / 13 (11.8) rs = 0.120 <0.05
32 (29.1) / 78 (70.9) rφ = 0.567 <0.01
0 / 110 (100) rφ = 0.796 <0.01
l type, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, ER
receptor 2, rs spearman rank order correlation, rφ phi coefficient. A small
Table 5 Logistic regression models for predicting TLS formation in breast carcinomas
Univariate analysis Multivariate analysis
OR 95% CI p value OR 95% CI p value
Tumor size (≤20 / 21–50 / >50 mm)
≤20 mm 1.00 (Reference) 1.00 (Reference)
21 - 50 mm 1.40 0.82 - 2.40 0.22 0.84 0.42 - 1.70 0.63
>50 mm 0.20 0.02 - 1.59 0.13 0.14 0.01 - 1.42 0.09
Tumor grade (I / II / III)
Grade 1 1.00 (Reference) 1.00 (Reference)
Grade 2 2.02 1.08 - 3.80 <0.05 1.53 0.72 - 3.26) 0.27
Grade 3 6.53 2.96 - 14.40 <0.01 2.78 1.06 - 7.27 <0.05
Immune cell infiltration (low / high) 13.97 7.78 - 25.09 <0.01 10.80 5.54 - 21.05 <0.01
Lymph node (− / +) 1.65 0.99 - 2.76 0.057 0.98 0.47 - 2.02 0.95
Abbreviations: OR odds ratio, CI confidence interval.
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metastasis did not affect the detection of intratumoral
TLS formation.
Discussion
It is well established that tumors of a variety of cancer
types are commonly infiltrated with immune cells which
are organized in structures resembling conventional
secondary lymphoid organs [41]. For the first time, we
describe intratumoral TLS formation in a larger group
of breast carcinoma patients. Our study demonstrates
that TLS are frequently found in breast tumors with
higher degree of immune cell infiltration and higher
histological tumor grade. Breast carcinoma cells are
often closely associated with tumor infiltrating lympho-
cytes [42]. Invasive carcinomas (NST) are the most com-
mon type of breast cancer, but unlike subtypes such as
medullary and basal-like carcinomas characterized by
prominent inflammation, they have a more variable
lymphocytic infiltration [43]. Breast carcinomas often
contain infiltrating B and T lymphocytes, with dense
infiltrates occurring in approximately 20% of tumors,
and moderate infiltrates in about 50% [9,43].
Our results showed the presence of tumor-associated
TLS in about one third of the breast carcinomas. These
structures comprise distinct T cell zones and B lympho-
cytes segregated into follicles hosting functionally active
GC, exhibiting structural analogies with secondary
lymphoid tissues. The observed TLS were confined to
peritumoral areas, and were detected both in the periph-
ery and central tumor nests. We did not observe these
structures in non-tumor areas, indicating that these
structures were tumor-associated and may be a response
to the tumor microenvironment. Consistent with our
findings, lymphoid neogenesis has been reported in
several other neoplastic diseases [10-15]. TLS are also
frequently observed in chronic inflammatory conditionsin which sustained lymphocyte activation occurs in the
presence of persistent antigenic stimuli [16-19]. Whether
TLS can generate an intratumoral immune response in a
way similar to secondary lymphoid organs is still
unclear. Experimental data from mouse models have
provided evidence that adaptive immunity can be initi-
ated independently of secondary lymphoid organs [44].
Notably, studies have demonstrated that development of
TLS play a role in the induction of a local antitumor
immune response in neoplastic tissue in mice lacking
peripheral lymph nodes [45-47]. Recent data published
by Goc et al. suggests TLS as an important site for in
situ activation of tumor-associated lymphocytes and sup-
ports the contribution of these structures in generation of
a protective immune response in lung cancer [48]. Fur-
thermore, Gu-Trantien et al. demonstrated that CXCL13-
producing Tfh cells located in GC of breast tumors are
associated with organized lymphoid structures that may
produce an antitumor immune reaction [22]. In line with
previous works, we observed Bcl6+ B lymphocytes and
Tfh cells within GC which argue for functional ectopic
centers in breast tumors. Given that extra-nodal activation
of lymphocytes occurs in tumor-associated TLS and facili-
tates induction of local immune reactions, it makes sense
that this phenomenon could be beneficial in antitumor
immunity.
It has become generally accepted that the immune
system exerts a dual role in carcinogenesis. Thus, one
can not rule out the opposite protumoral effect as the
tumor eradication by the immune system is often ineffi-
cient, and spontaneous or complete regression of estab-
lished tumors are extremely rare [49]. The immunoediting
theory emphasizes that during tumor development and
progression, there is a dynamic interaction between the
host immune system and the developing tumor, a process
which describes the host-protective and tumor promoting
roles of the immune system [50]. Studies in mouse models
Figenschau et al. BMC Cancer  (2015) 15:101 Page 9 of 11suggest that CCL21 secreting tumors may alter the locally
generated immune response by promoting tumor-induced
tolerance, which facilitates tumor progression [51]. In
addition, impairment of antitumoral T cell responses and
modulation of immune responses by immune complexes
might represent underlying mechanisms that also pro-
mote tumor progression [52]. The immunoediting theory
was recently further challenged by Ciampricotti et al. who
evaluated the role of adaptive immune responses in
tumorigenesis by establishing a mouse model of spontan-
eous HER2+ breast tumors. The study demonstrated that
the development of tumors were not suppressed by
immunosurveillance mechanisms or influenced by adap-
tive immune responses [53]. Interestingly, a recent study
showed decreased density of HEV and DC-LAMP+ DCs
around the DCIS component compared to invasive areas
in breast tumors, suggesting to be a key feature in the pro-
gression from in situ to invasive carcinoma [37]. However,
our results did not show a strong association between
the presence of TLS and DCIS components within the
invasive tumors. Taken together, there are examples
where TLS formation in neoplastic diseases is associ-
ated with promotion of tumorigenesis rather than gen-
erating a protective immune response. Still, the overall
morphology of a conventional secondary lymphoid
organ with Bcl6+ GC cells combined with specialized
population of DC and distinct T cell area are convin-
cing findings of local adaptive immune response taking
place in these structures.
The major finding of our study demonstrated that
higher tumor grade was associated with intratumoral
TLS formation. Tumors with histological grade 3 are the
most aggressive types and are associated with worst
prognosis. Lymph node metastases are also associated
with worse prognosis independent of tumor grade. Our
results demonstrated a weak association between the
presence of intratumoral TLS and lymph node involve-
ment. It is therefore important to address whether TLS
would influence the clinical outcome in a larger series of
breast cancer patients. The formation of TLS with mor-
phologically and immunophenotypically identical fea-
tures to a conventional secondary lymphoid organ is
intriguing, and adds to the findings of similar structures
in malignant tumors in other organ systems [10-15]. In
addition, as previously mentioned, immune cell infiltra-
tion in tumors is associated with prognosis and survival
of breast cancer patients. The distinct combination of
tumor infiltrating immune cells combined with lymph-
oid neogenesis may suggest TLS as a biomarker in
cancer. Hence, the importance of defining the immuno-
phenotype, the location and the functionality of the
immune infiltrates in breast carcinomas may become
useful in predicting a patient’s prognosis. Careful studies
on the mechanisms of the immune reactions and theirimpact at different stages of disease should hopefully
result in an improved approach to targeted therapies.
Conclusion
In this study, we characterized tertiary lymphoid struc-
tures in breast cancer patients and addressed the ques-
tion whether there was a relationship between immune
cells infiltrating human breast tumors, intratumoral for-
mation of TLS and clinicopathological parameters. Our
main findings conclude that tumors with higher degree
of immune cell infiltration also have higher tumor grade.
In addition, intratumoral TLS formation was associated
with higher inflammation grade and higher tumor grade.
These findings support the notion that infiltrating im-
mune cells are a common feature in breast cancer tumors
and that breast tumors frequently contain tertiary lymph-
oid structures.
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